Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
7.4
5.2
Journals
Cancers
Special Issues
Novel Drugs for Treating Gynecologic Cancers
share announcement

Novel Drugs for Treating Gynecologic Cancers

A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Cancer Drug Development".

Deadline for manuscript submissions: closed (30 April 2024) | Viewed by 1347

Special Issue Editors

Prof. Dr. Tadahiro Shoji

E-Mail
Guest Editor
Department of Obstetrics and Gynecology, Iwate Medical University, Yahaba, Japan
Interests: ovarian cancer; chemotherapy; cellular diagnostics
Prof. Dr. Hiroaki Itamochi

E-Mail Website
Guest Editor
Department of Clinical Oncology, Iwate Medical University, Yahaba, Japan
Interests: gynecological cancer; ovarian cancer; endometrial cancer; cervical cancer; molecular biology; molecular genetics
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

This Special Issue is titled “Novel Drugs for Treating Gynecologic Cancers”.

Gynecologic cancer treatment has reached a major turning point thanks to the development of molecularly targeted agents and immune-checkpoint inhibitors.

In particular, in ovarian cancer treatment, testing for BRCA and HRD status is expected to further improve prognosis by combining molecular targeted agents with different mechanisms of action.

This Special Issue aims to collect original research studies and review articles (either systematic or discursive), clinical trials, and short communications adding to the current knowledge and showing potential future approaches of novel agents for gynecologic cancers.

Prof. Dr. Tadahiro Shoji
Prof. Dr. Hiroaki Itamochi
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • gynecological cancers
  • novel treatment strategies
  • cytotoxic chemotherapeutic agents
  • molecularly targeted agents
  • immune-checkpoint inhibitors

Published Papers (1 paper)

Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

9 pages, 444 KiB  
Article
A Phase II Study of S-1 plus Oxaliplatin for Patients with Recurrent Non-Squamous Cell Carcinoma of the Uterine Cervix (Tohoku Gynecologic Cancer Unit: TGCU206 Study)
by Takayuki Nagasawa, Tadahiro Shoji, Eriko Takatori, Yoshitaka Kaido, Masahiro Kagabu, Dai Shimizu, Tatsuhiko Shigeto, Tsukasa Baba, Toru Sugiyama and Yoshihito Yokoyama
Cancers 2023, 15(21), 5201; https://doi.org/10.3390/cancers15215201 - 29 Oct 2023
Viewed by 937
Abstract
Recurrent non-squamous cell carcinoma (non-SCC) of the uterine cervix is resistant to treatment and has a poor prognosis. The efficacy and safety of S-1/oxaliplatin (SOX) therapy in patients with recurrent non-SCC was examined in a phase II study. Fifteen patients were enrolled between [...] Read more.
Recurrent non-squamous cell carcinoma (non-SCC) of the uterine cervix is resistant to treatment and has a poor prognosis. The efficacy and safety of S-1/oxaliplatin (SOX) therapy in patients with recurrent non-SCC was examined in a phase II study. Fifteen patients were enrolled between August 2013 and March 2023. S-1 was administered orally at a daily dose of 80–120 mg for 14 days, and oxaliplatin was administered intravenously at a dose of 100 mg/m2 on day 1. Each treatment cycle lasted 21 days. The anti-tumor effects, adverse events, progression-free survival (PFS), and overall survival (OS) were investigated. The median patient age was 54 (41–74) years. The anti-tumor effect was rated as a partial response in five patients, stable disease in four, and progressive disease in 6. The overall response rate was 33% and the disease control rate was 60%. Regarding hematologic toxicities of grade 3 or more severity, leukopenia, neutropenia, anemia, and thrombocytopenia occurred in 26.6–40.0%. None of the patients discontinued the treatment because of adverse events. The median PFS and OS were 6 months (95% confidence interval [CI]: 2–11 months) and 22 months (95% CI: 11–23 months), respectively. No treatment-related deaths occurred. These results suggest that SOX therapy is useful for the treatment of recurrent non-SCC with promising anti-tumor effects and minimal adverse events. Full article
(This article belongs to the Special Issue Novel Drugs for Treating Gynecologic Cancers)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-1
Back to TopTop